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E-mail address: AHu@salud.unm.edu (C.-A.A. Hu).Human apolipoprotein L1 (ApoL1) possesses both extra- and intra-cellular functions crucial in host
defense and cellular homeostatic mechanisms. Alterations in ApoL1 function due to genetic, envi-
ronmental, and lifestyle factors have been associated with African sleeping sickness, atherosclerosis,
lipid disorders, obesity, schizophrenia, cancer, and chronic kidney disease (CKD). Importantly, two
alleles of APOL1 carrying three coding-sequence variants have been linked to CKD, particularly in
Sub-Saharan Africans and African Americans. Intracellularly, elevated ApoL1 can induce autophagy
and autophagy-associated cell death, which may be critical in the maintenance of cellular homeo-
stasis in the kidney. Similarly, ApoL1 may protect kidney cells against renal cell carcinoma (RCC).
We summarize the role of ApoL1 in RCC and CKD, highlighting the critical function of ApoL1 in
autophagy.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction [10,18], other human apolipoproteins, and Bcl-2 family proteinsSince the identiﬁcation and characterization of human apolipo-
protein L1 (ApoL1) as an interacting protein of apolipoprotein A1
(ApoA1) and a minor component of high density lipoprotein
(HDL) particles in 1997 [1], the human ApoL protein family was
thought to be predominantly involved in lipid transport and
metabolism [1–6]. In fact, several lines of evidence indicate that
ApoLs are associated with hyperlipidemia, obesity and atheroscle-
rosis [2,4–6]. However, recent studies have identiﬁed novel roles
for ApoL proteins in host innate immunity [7–13], apoptosis
[14,15] and autophagy [16,17], which can be attributed, in part,
to the structural similarities between ApoLs and bacterial colicinschemical Societies. Published by E
ic kidney disease; ESKD, end
rulosclerosis; HIVAN, HIV-1
Biochemistry and Molecular
buquerque, NM 87131-0001,[14,17–19]. The human APOL family consists of six genes localized
in chromosome 22q12.3 to 13.1 [3,18–21], a genomic hotspot for a
number of diseases, including schizophrenia [22–28], prostate can-
cer [29,30], and liver and breast cancer [31,32]. More recently, two
alleles of APOL1 harboring three coding-sequence variants have
been discovered in kidney disease patients of African ancestry
and linked to the pathogenesis of non-diabetic chronic kidney dis-
ease (CKD), including idiopathic focal and segmental glomerulo-
sclerosis (FSGS), hypertension-attributed kidney disease, and
HIV-1-associated nephropathy (HIVAN), under a recessive inheri-
tance pattern [33–39]. The expression of APOL1 has been detected
in renal proximal tubular epithelial cells [19], podocytes and pre-
glomerular vascular structures [40], suggesting that ApoL1 could
play a role in the pathogenesis of renal diseases that affects the
structure and/or function of these cells. Moreover, these APOL1
variants have been considered potentially risk factors for
predicting the histopathology and progression of HIVAN [41] as
well as kidney transplant rejection [42,43]. Similarly, given the
results of previous studies showing a potential role of ApoL1 in
tumorigenesis, and its expression in renal proximal tubular cells,lsevier B.V. All rights reserved.
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macroautophagy (hereafter referred to as autophagy), may also
play a role in the pathogenesis of renal cell carcinoma (RCC). For
all the above reasons, this review will summarize and discuss the
role of ApoL1 in RCC and CKD, highlighting the critical function
of ApoL1 in autophagy.2. ApoL1 in autophagy and autophagy-associated cell death
We have recently shown that ApoL1 is a novel BH3-only protein
and, when overexpressed intracellularly, induces autophagy and
autophagy-associated cell death in a variety of cell types [16,17].
However, the intracellular role of ApoL1 in vivo has not been
investigated. Interestingly, lack of functional autophagy has been
shown to correlate with the outcome of various diseases, including
cancer, cardiomyopathies, inﬂammatory bowel disease, obesity,
neurodegenerative diseases, and CKD [44–48]. Autophagy is a
conserved, lysosomal-dependent mechanism that involves the
sequestration and degradation of intracellular constituents. In this
process, a fraction of cytosolic proteins and organelles is ﬁrst
enwrapped within a double-membrane organelle, referred to as
the autophagosome. Subsequently, the autophagosome fuses with
endosomes and lysosomes to form two other types of autophagic
vesicles, amphisomes and autolysosomes, in mammalian cells. This
process results in the degradation of the sequestered materials by
lysosomal enzymes in the autolysosome (Fig. 1) [46]. Autophagy is
a catabolic active process that generates amino acids, fatty acids,
glucose and nucleotides, which can be recycled to produce energy
and building blocks for the survival of cells [47]. In this manner,
low physiological levels of autophagy is necessary to preserve
the homeostasis and function of cells, and facilitate the turnover
of proteins, organelles and lipid droplets. In addition, autophagy
can also function as a survival mechanism during times of acute
or chronic stress through the elimination and recycling of dam-
aged/aggregated proteins and organelles. It has been demonstrated
in mammalian cells that the induction of autophagy, for example in
response to starvation, is mediated in part via inactivation of the
mammalian target of rapamycin (mTOR) complex 1 (mTORC1),
by p53 and/or other factors [48–50]. Interestingly, two of the p53
downstream targets, Bnip3 and DRAM, have been shown to
directly regulate autophagy (Fig. 1). Upon autophagy induction,
mTORC1 is inactivated leading to the activation of ULK1 complex
(including ULK1, Atg13, FIP200, and Atg101), that in turn activates
the class III phosphatidylinositol 3-kinase complex, including
Vps34, Vps15, Beclin 1, Barkor/Atg14L, and Ambra1 [46,47]. Beclin
1, the mammalian homolog of yeast Atg6, is a BH3-only protein
required for autophagy and is regulated by Bcl-2 family members
and other interacting proteins [51,52]. The elongation of phago-
phore membranes into autophagosomes is regulated by three
ubiquitination-like reactions. First, the ubiquitin-like molecule
Atg12 is conjugated to Atg5 by Atg7, which acts like an E1 ubiqui-
tin-activating enzyme, and by Atg10, which is similar to an E2
ubiquitin-conjugating enzyme. The Atg5–Atg12 complex then
interacts non-covalently with Atg16L1 and this resulting the
Atg12–Atg5–Atg16L1 complex associates with phagophores but
dissociates from mature autophagosomes [53]. The second ubiqui-
tin-like reaction involves the conjugation of mammalian LC3-II,
GABARAP and GATE-16, homologs of yeast Atg8 [54], to phospha-
tidylethanolamine (PE) by Atg7 and Atg3 (another E2-like), result-
ing in autophagosome-associated LC3-II. The Atg12–Atg5 complex
may be able to enhance LC3-II conjugation to PE by acting in an
E3-like fashion. In this way, the Atg12–Atg5–Atg16L1 complex
may determine the sites of autophagosome synthesis by regulating
the targeting of LC3-II to Atg12–Atg5-associated membranes.
Interestingly, LC3-II remains associated with autophagosomesuntil after their fusion with lysosomes. The LC3-II inside the
autolysosomes is degraded, while the LC3-II on the cytoplasmic
surface can be delipidated and recycled. Thus, Atg12–Atg5–
Atg16L1-positive and LC3-positive structures can be considered
to be phagophores and Atg12–Atg5–Atg16L1-negative and
LC3-positive vesicles can be regarded as mature autophagosomes
[55,56]. P62, also known as sequestosome 1/SQSTM1, is an ubiqui-
tously expressed protein and one of the best characterized sub-
strates of selective autophagy. p62 has been shown to directly
interacts with LC3-II on the phagophore through the LC3-interact-
ing region. Subsequently, p62 is incorporated into the autophago-
some and then degraded (Fig. 1). Impairment of autophagy is
accompanied by accumulation of p62. This leads to the formation
of large aggregates, which include p62 and ubiquitinated proteins.
P62 also has been implicated in the recognition process of autoph-
agy-mediated degradation of damaged mitochondria, known as
mitophagy. However, the precise mechanism is still under investi-
gation [46,57]. Notably, ApoL1, which its expression is inducible by
p53, is found highly expressed in cells undergoing elevated levels
of autophagy including renal tubular epithelial cell and pancreatic
exocrine granular cells ([19] and The Human Protein Atlas website
http://www.proteinatlas.org/ENSG00000100342). Moreover, pre-
vious studies using immunoblot analysis have shown a time-
dependent accumulation of LC3-II, and an increase in the LC3-II
to LC3-I ratio in cells overexpressing ApoL1. These ﬁndings suggest
that overexpression of ApoL1 induces autophagy, which is partially
inhibited in murine Atg5/ and Atg7/ embryonic ﬁbroblast cells.
In addition, 3-methyladenine and wortmannin, two inhibitors of
PI3KCIII and thus autophagy, also can reduce ApoL1-induced cell
death [16]. Thus, one mechanism of ApoL1-induced autophagy
may involve, directly or indirectly, activation of the translocation
of LC3-II to the autophagosome (Fig. 1). Interestingly, we recently
observed that ApoL1–EGFP fusion protein was localized in the
cytosol and lysosomes (Fig. 2A), suggesting that ApoL1-regulated
autophagy, for survival or for death, may involve lysosomes. Nev-
ertheless, as autophagy is a bona ﬁde stress responsive mechanism
and usually activated during cell death progression, the role of
autophagy in autophagy-associated cell death is still under
intensive investigation and there are numerous lines of evidence
support either cells died with autophagy [58–62] or died of
autophagy [62–66].3. ApoL1, autophagy, and cancer
As stated above, intracellular accumulation of ApoL1 has been
linked to the processes of autophagy and cell death. Others have
shown that genetic, biochemical or pharmacological inhibition of
autophagy results in increased free radicals, aggregated macro-
molecules, elevated DNA damage and metabolic deﬁciencies that
lead to global cellular damage and apoptosis [67,68]. For all these
reasons, alterations in proteins that impair the process of apoptosis
and autophagy have been linked to the pathogenesis of different
types of cancers. It is worth noting however, that the process of cell
death in mammalian cells is often preceded or accompanied by
autophagic vacuolization [58–62]. This ﬁnding, raises the contro-
versial issue of whether autophagy per se, directly induces cell
death, or alternatively, it is just an epiphenomenon seen in cells
under stress that are destined to die. This notion is supported by
the results of mouse studies, in which knockouts of essential
autophagy genes showed that several chemotherapy drugs pre-
vented the growth of tumor cells without affecting the process of
‘‘autophagic cell death’’ [61]. Nevertheless, even, assuming the
autophagy may be a secondary phenomenon seen in cells
subjected to severe stress destined to die, many studies have
suggested that it can play a role in the pathogenesis of several
Fig. 1. The role and subcellular localization of ApoL1 in autophagy in human cells. A wealth of literature has shown that expression of APOL1 can be induced by the signaling
pathways of IFN-c, TNF-a and p53. Intracellularly, ApoL1 is lysosomal and cytosolic (see Fig. 2A), and can induce (macro)autophagy and autophagy-associated cell death
when overexpressed. Interestingly, another lysosomal protein, DRAM, also a p53 downstream target, can induce autophagy and apoptosis. Autophagy, a lysosome-dependent,
self-eating, and catabolic mechanism, can be initiated by various stresses (for example, starvation, inﬂammatory cytokines, and pathogens). Upon autophagy induction,
mTORC1 is inactivated leading to the activation of ULK1 complex (including ULK1, Atg13, FIP200, and Atg101), that in turn activates the class III phosphatidylinositol 3-kinase
complex, including at least Vps34, Vps15, and Beclin 1. The elongation of phagophore membranes into autophagosomes is regulated by two ubiquitination-like reactions.
First, the ubiquitin-like molecule Atg12 is conjugated to Atg5 by Atg7, which acts like an E1 ubiquitin-activating enzyme, and by Atg10, which is similar to an E2 ubiquitin-
conjugating enzyme. The Atg5–Atg12 complex then interacts non-covalently with Atg16L1 and this resulting the Atg12–Atg5–Atg16L1 complex associates with phagophores
but dissociates from mature autophagosomes. The second ubiquitin-like reaction involves the conjugation of mammalian LC3-II, a homolog of yeast Atg8, to
phosphatidylethanolamine (PE) by Atg7 and Atg3 (another E2-like), resulting in autophagosome-associated LC3-II. The Atg12–Atg5 complex may be able to enhance LC3-II
conjugation to PE by acting in an E3-like fashion. In this way, the Atg12–Atg5–Atg16L1 complex may determine the sites of autophagosome synthesis by regulating the
targeting of LC3-II to Atg12–Atg5-associated membranes. Interestingly, LC3-II remains associated with autophagosomes until after their fusion with lysosomes. The LC3-II
inside the autolysosomes is degraded, while the LC3-II on the cytoplasmic surface can be delipidated and recycled. Subsequently, the autophagosome fuses with endosomes
and lysosomes to form two other types of autophagic vesicles, amphisomes and autolysosomes in human cells. This process results in the degradation of the sequestered
materials by lysosomal hydrolases in the autolysosome. P62, an ubiquitously expressed protein, is one of the best characterized substrates of selective autophagy and
mitophagy. P62 has been shown to bind polyubiquinated proteins and possibly damaged mitochondria and directly interact with LC3-II on the phagophore through the LC3-
interacting region. Subsequently, p62–cargo complex is incorporated into the autophagosome and then degraded. Mitophagy has been shown to be regulated by Bnip3, a
BH3-only protein and a p53 downstream target. Extracellularly, ApoL1 is an interacting protein of ApoA1 in lipoprotein complexes.
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mas, tumors associated with tuberous sclerosis, and pancreatic
cancer [58,60,62]. For example, pancreatic cancers have been
shown to depend on autophagy for survival. More speciﬁcally,
pancreatic ductal adenocarcinoma cells (PDAC) exhibit constitutive
upregulated autophagy under basal conditions, most likely due to
the hypoxic environment present within tumors [69]. In turn,
acquired alterations in autophagy may allow PDAC cells to survive
under high stress conditions. Further, inhibition or targeted regula-
tion of autophagy within these cells may provide a therapeutic
treatment for cancers that require elevated autophagic activity. It
is worth noting that mice with systemic mosaic deletion of Atg5
and liver-speciﬁc Atg7/ developed benign liver adenomas [70].
These tumor cells originated from autophagy-deﬁcient liver cells
and showed mitochondrial swelling, p62 accumulation, oxidative
stress and DNA damage responses. The size of the Atg7/ liver
tumors is reduced by simultaneous deletion of p62. Together, these
results suggest that autophagy is important for the suppression of
spontaneous tumorigenesis through a cell-intrinsic mechanismin the liver, and that p62 accumulation contributes to tumor
progression [70]. In contrast, the role of autophagy in kidney
pathology was recognized just recently. In 2007, Chien et al.
showed the induction of Beclin 1 and LC3-II during kidney
ischemia–reperfusion in rats, and both autophagy and apoptosis
were suppressed by the expression of Bcl-XL and Bcl-2 [63]. Suzuki
et al. further demonstrated the formation of autophagosome-like
structures in renal tubular cells during ischemia–reperfusion in
mice and, notably, in transplanted kidneys in humans [64]. In
cultured tubular cells, autophagy inhibitors could suppress H2O2-
induced cell death, suggesting that autophagy might contribute
to cell death under these conditions [64]. Very recently, Gozuacik
et al. showed autophagy in renal tubular cells following tunica-
mycin-induced ER stress in mice, and autophagy may serve as a
second cell-killing mechanism, or type II programmed cell death,
that acts in concert with apoptosis during ER stress [65]. Taken
together, it is evident that either too much or too little autophagic
activity can affect the regulation of cell growth in a signiﬁcant
manner.
Fig. 2. (A). Human ApoL1 localizes in the cytosol and lysosomes. Confocal microscopy analysis showed that EGFP-ApoL1 fusion protein (in green) and the lysotracker (in red)
were co-localized (in yellow) almost perfectly in human ﬁbroblast cells, suggesting that human ApoL1 is mainly lysosomal. (B). Non-synonymous SNPs, domains and motifs of
human ApoL1 isoforms. Three ApoL1 isoforms can be generated by alternative splicing. ApoL1.a, a 398 amino-acid (aa) polypeptide, is shown in its complete sequence.
ApoL1.b is 16 aa N-ter longer than ApoL1.a (shown in orange), while ApoL1.c is missing a 18 aa motif (shown in blue and underlined) close to the N-ter of ApoL1.a.
Interestingly, fourteen naturally occurring, non-synonymous variant/alleles of APOL1 have been identiﬁed thus far, based on the residue numbers of ApoL1.a, N95K, G96R,
K142fs, E150K, N176S, M218I, R255K, N264K, L266fs, G270D, D337N, S342G, I384M and DN388Y389 (amino acid changes are in red). The BH3 domain (codons 158–166) and
the leucine zipper domain (codons 365–392) are in bold and underlined. The two risk alleles of APOL1 in ESKD in African Americans, S342G/I384M andDN388Y389, are in the
C-ter domain (highlighted in yellow; codons 342 to 398), which interacts with trypanosomal SRA (see text). Interestingly, I384M mutation is present in the leucine zipper
domain, which may affect binding of ApoL1 with other proteins in human cells. K142fs and L266fs alleles were identiﬁed in an Indian patient whose serum lacked the TLF
activity [101]. ", indicates the putative signal peptide, an N-ter 27 aa leader sequence of ApoL1.a); ∇ , putative proteolytic cleavage site (between D andW) to generate 39 kDa
form of ApoL1. N261, a potential N-glycosylation site. The alpha helixes (a-2 to 10) in the protein are also indicated (in pink).
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RCC is among the ten leading causes of cancer related deaths,
and accounts for 2% of all cancers [71–73]. RCC occurs in a sporadic
and a hereditary form, and both forms are frequently associated
with structural alterations of the short arm of chromosome 3
(i.e., 3p). Genetic studies of the families at high risk for developing
RCC led to the cloning of genes whose alteration results in tumorformation. These genes are either tumor suppressors (e.g., VHL,
TSC) or oncogenes (e.g., MET, RAS). RCC originates in proximal
renal tubular epithelial cells, which have, among other functions,
an important role in the absorption and transport of water, glucose,
salt, and several nutrients [74,75]. These processes require a signif-
icant amount of energy and therefore proximal tubules have a well
developed lysosomal system to participate in the reabsorption and
degradation of albumin and other low molecular weight plasma
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erating cells consume energy and require an active lysosomal sys-
tem to degrade and recycle proteins, lipids and amino acids that
are needed for the process of cell growth [47]. For all these reasons,
it is tempting to speculate that autophagy may play a critical role
modulating the growth, regeneration, and survival of proximal
tubular cells. We have found high levels of ApoL1 protein in renal
tubular epithelial cells [19], and these ﬁndings also suggest that
ApoL1 may play an active role in these processes. In support of this
notion, autophagy has been shown to be renal protective during
acute ischemic injury [76–78] and cisplatin-induced kidney injury
in mice [79–81]. More speciﬁcally, these studies showed that
cisplatin can induce the formation of autophagic vesicles in renal
proximal tubular epithelial cells. These changes appear to be
mediated by p53 and modulated by anti-death proteins, like
Bcl-2 [80,81]. Thus, given the fact that renal proximal tubular
epithelial cells show signiﬁcant p53-associated autophagic activity
under stress and express considerable amounts of ApoL1 [19], it is
worth discussing the potential interactions that p53, ApoL1, and
autophagy may have in the pathogenesis of RCC.
RCC usually maintains a wild type p53 tumor suppressor gene,
however, the function of p53 could be modulated by other mech-
anisms including alterations in the RAS, PI3K/AKT/mTOR and/or
NF-jB pathways in RCC [71,73,82]. In addition, it is well known
that activation of p53 by various stresses can induce autophagy
in cancer cells [49,83,84]. Interestingly, we observed a time-depen-
dent expression of APOL1 in a number of cell lines overexpressing
wildtype nuclear p53. Thus, one pathway by which p53 induces
autophagy could be through the intracellular accumulation of
ApoL1 that leads to activation and translocation of LC3-II and/or
changing the homeostasis of phospholipids [17]. In addition,
inhibitors of PI3KCIII and therefore autophagy also reduced
ApoL1-induced cell death. Furthermore, we recently observed
downregulated expression of ApoL1 in RCC tissues and cell lines
(Hu et al., unpublished observations). These ﬁndings suggest that
ApoL1 could be an important signaling protein that is targeted to
elimination by RCC cells for their survival advantage. It should be
noted, however, that mice with Atg5 targeted deletion in the
proximal tubules did not develop kidney tumors but exhibited
accumulation of misfolded proteins and deformed organelles, and
were susceptible to ischemia–reperfusion injury [76]. These mice
only showed hypertrophic changes in renal proximal tubular cells,
suggesting that, unlike the liver-speciﬁc autophagy-deﬁcient mice
that develop liver tumors, suppression of autophagy in kidney
proximal tubular epithelial cells do not cause kidney tumors. These
ﬁndings are consistent with the notion that other alterations in
tumor suppressor genes and/or oncogenes are required for the
development of RCC. Unfortunately, since rodents do not carry
APOL1 gene, it is difﬁcult to study the potential interactions
between autophagy and ApoL1 in the pathogenesis of renal tumors
or RCC in rodents.5. ApoL1 and CKD
Chronic kidney disease (CKD) encompasses a group of renal
lesions caused by a variety of etiological factors that destroy the
renal parenchyma and decrease the renal function. For example,
the term focal and segmental glomerulosclerosis (FSGS), which
deﬁnes a renal glomerular lesion associated with CKD, represents
a common and ﬁnal injury pathway, used by different primary or
secondary renal diseases, hypertension, toxins, drugs, and viral
infections [85]. The National Kidney Foundation classiﬁes CKD in
ﬁve stages based on the extent of renal damage and pathological
events including glomerular ﬁltration rate, renal excretory
function, plasma creatinine, proteinuria levels, and percent offunctionally active nephrons [86]. Although diabetes and
hypertension are the leading causes of stage 5 kidney disease, also
referred to as end stage kidney disease (ESKD), many other
environmental, genetic, and lifestyle factors have been associated
with CKD.
The kidney ﬁltration barrier comprises a complex framework
of renal structures that include glomerular endothelial cells,
extracellular matrix proteins that constitute the basement mem-
brane, and podocytes. Podocytes are terminally differentiated
cells surrounding the glomerular capillaries. The long processes
or ‘‘foot projections’’ of the podocytes wrap around capillaries
interdigitate with one another forming ﬁltration slits that are
highly permeable to water, small solutes and ions, but restrict
the passage of albumin, large molecules, and cells into the glo-
merular ﬁltrate [86]. In addition, injured mesangial cells, which
are specialized contractile smooth muscle cells that provide
structural support to renal glomeruli, can decrease the glomeru-
lar ﬁltration rate (GFR). In CKD, the kidney’s ability to maintain
the GFR and other renal functions is impaired, preventing the
clearance of waste products and toxic metabolites from the blood
and urinary ﬁltrate. Ultimately, these changes further compro-
mise the structure of renal glomeruli and tubules and affect
the homeostasis of the whole body [86]. In essence, CKD can
be the result of many pathological insults and processes that af-
fect different glomerular and tubulo-interstitial cells. In recent
years podocyte injury has been considered a major culprit for
the development of FSGS. Moreover, the chronic loss of podo-
cytes in the urine is considered an important factor leading to
FSGS and CKD. Inﬂammation, stress-induced damage, changes
in lipid proﬁles, viral infections, hypertension, and alterations
of survival and autophagic pathways have also been shown to
contribute to the pathogenesis of glomerular and tubulointersti-
tial injury leading to CKD [85,86]. Interestingly, recent studies
have suggested several mechanisms by which reduced autophagy
can affect the function of podocytes, proximal renal tubular epi-
thelial cells, and the pathophysiology of different renal diseases
[62,79]. In addition, ApoL1 is detected in normal podocytes,
and its expression appears to be reduced in patients with FSGS
and HIVAN [40]. Taken together, these ﬁndings suggest that the
APOL1 risk variants may modulate the outcome of these kidney
diseases by affecting the function of podocytes. For example,
mice with podocyte-speciﬁc deletion of Atg5 showed proteinuria
and a progressive decline in renal function [87]. After 20 months,
mice displayed signiﬁcant global and segmental glomerulosclero-
sis (GSGS) or FSGS caused by puromycin aminonucleoside and
adriamycin, which normally upregulated autophagic activity in
intact podocytes [87]. As podocytes are the primary target for
toxic aggregates and oxidative stress, it could be hypothesized
that accumulation protein aggregates and damaged organelles
in autophagy-deﬁcient podocytes, may overwhelm the intracellu-
lar degradation pathway of ubiquitinated proteins and induce
CKD. Interestingly, 22-month-old Atg5/ mice presented a sig-
niﬁcant reduction in the number of podocytes in non-sclerosed
glomeruli, suggesting that podocyte loss precedes the develop-
ment of FSGS [87]. In addition, studies have found increased lev-
els of Atg3 mRNA in podocytes from patients with FSGS relative
to control renal samples [87]. Moreover, genetic alterations in
several proteins expressed by podocytes, including nephrin,
podocin, and CD2, are also associated with the development of
glomerulosclerosis [85–89]. Since podocytes appear to require
and exhibit high levels of autophagy [90], they may rely on this
mechanism to ﬁght stressful situations. Consequently, autophagic
balance of podocytes appears to be essential mechanism to
preserve the renal function, and loss of autophagic capabilities
may be an important contributing factor for the development
of ESKD.
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It has been well known for years that various kidney diseases
that cause FSGS are clustered among populations of African des-
cent. Recent linkage and mapping genetic analyses have demon-
strated that two alleles containing variants in the last exon of the
APOL1 gene appear to explain the striking racial disparities in the
frequency of idiopathic FSGS, hypertension-attributed ESKD, and
HIVAN between African Americans and European Americans
[19,33,34,36–41,91]. These studies have localized a region in chro-
mosome 22q12-13 that harbors the MYH9 and APOL1 genes, which
possess risk variants associated with FSGS, ESKD, and HIVAN in
people of African ancestry [33–43]. As stated above, ApoL1 is
essential for its primate-speciﬁc role in autophagy, the N-terminal
(N-ter) and C-terminal (C-ter) contain domains/motifs vital to its
localization, translocation, induction of autophagy, and immunity
effector functions. In fact, there are three protein isoforms, Apo-
L1.a, ApoL1.b and ApoL1.c, encoded by four putative human APOL1
mRNA variants [19]. ApoL1.a, a 398 amino-acid (aa) polypeptide, is
the most abundant and relatively well-studied protein. Resulting
from alternatively splicing, ApoL1.b, 414 aa, is 16 aa N-ter longer
than ApoL1.a, while ApoL1.c, 380 aa, is missing a 18 aa motif close
to the N-ter of ApoL1.a due to alternative splicing (Fig. 2B). Using
ApoL1.a as an example, besides the BH3 domain (codons 158–
166), there is a leucine zipper domain (LZD; codons 365–392) in
ApoL1. The N-ter of ApoL1 isoforms consist of an anionic pore-
forming domain thought to be involved in anion channel formation
and cell death in trypanosomes. Adjacent to the pore-forming
domain is the membrane-addressing domain, which consists of
pH-sensitive a-helices and facilitates the association with HDL
particles at a neutral pH or intracellular regions at an acidic pH.
Moreover, C-ter of ApoL1 possesses an amphipathic a-helix
containing the LZD embedded in the serum resistance-associated
protein (SRA) interacting domain (see below). Mounting evidence
has suggested a vital role for the LZD in protein–protein interaction
[92,93]. Interestingly, it has been shown that the LZD may also
bind lipid species and DNA to promote signal transduction. For
example, Yamamoto and Ryan have revealed that the LZD of
ApoE3 confers stability to the N-ter domain in an inactive state.
When the LZD interacted with surface binding sites of lipoprotein
complexes, it resulted in the anchoring of ApoE3 to the lipid parti-
cle surface, which facilitates a conformational change of the N-ter
helices [93]. In turn, it can be speculated that binding of the LZD of
ApoL1 to other components of lipoprotein particles and/or mem-
brane receptors promotes structural changes of ApoL1, allowing
for the functional properties of the N-ter and the BH3 domains of
ApoL1.
With regard to the link of ApoL1 and CKD, there are two haplo-
types of APOL1, harboring three coding sequence mutations, have
been identiﬁed as risk variants in this region. The ﬁrst one, termed
G1, is a two non-synonymous SNP (NSNP) haplotype (rs73885319
(A?G; S342G) and rs60910145 (G?T; I384M). The second one,
termed G2, is a two codon deletion haplotype rs71785313 (6-bp
in frame deletion; DN388Y389). Interestingly, the frequency of
the APOL1 G1 haplotype distributed in African populations is con-
sistent with the pattern of African ancestry risk of developing ESKD
[34]. In fact, based on odds ratios and p values APOL1 risk variants
are more strongly associated with ESKD than the leading MYH9
risk variants. Aside from the 5 NSNPs mentioned above, other
naturally occurring, non-synonymous variant/alleles of APOL1
have been identiﬁed. According to the residue numbers of ApoL1.a,
they are N95K, G96R, E150K, N176S, M218I, R255K, N264K, G270D,
and D337N, suggesting that ApoL1 is very polymorphic (Fig. 2B). It
is logical to speculate that protein products of some of these NSNPsmay have altered activity, stability or subcellular localization of
ApoL1.
It is worthy noting that extracellular ApoL1 is a crucial compo-
nent of human trypanolytic factors (TLF) that provide resistance
against trypanosomes, including Trypanosoma brucei brucei. There
are a number of excellent papers already documenting this
particular important area of research [7–13,94–100]. While two
types of TLF, TLF1 and TLF2, have been identiﬁed thus far, TLF1 is
relatively well studied, shown to be resided in a minor subclass
of serum HDL, which contains two primate speciﬁc proteins, ApoL1
and haptoglobin-related protein (Hpr), as well as ApoAI. These
protein complexes provide an important defense mechanism
against the ﬂagellated parasitic protozoa trypanosome. ApoL1
alone has been shown to be sufﬁcient to confer trypanolytic activ-
ity in vitro and in vivo [94–97]. Regarding TLF1-resistant trypano-
somes, they produce the SRA, which binds speciﬁcally to ApoL1 of
TLF1. Microscopic analysis demonstrated that ApoL1 uptaken by
trypanosomes is targeted to the lysosome, leading to the formation
of anion channels, triggering the depolarization of the lysosomal
membrane, and causing an inﬂux of chloride that leads to the os-
motic swelling of the lysosome until the parasite dies [9,10,13].
Formation of the SRA–ApoL1 complex prevents killing and allows
parasite growth in humans. It has been shown that SRA directly
interacts with the C-ter a-helical region of ApoL1 (Fig. 2B). We
have reported that APOL1 expression can be induced by circulating
inﬂammatory cytokines, including interferon-c (IFN-c) and tumor
necrosis factor-a (TNF-a), further supporting the role of ApoL1 in
extracellular innate immunity [16,17,19]. Importantly, variants of
G1 and G2 alleles are located in the last exon resulting in codon
changes in both SRA-binding and the LZD in the C-ter of ApoL1 iso-
forms. Consequently, protein products of the G1 and G2 alleles can
effectively lyse serum-resistant Trypanosoma brucei rhodesiense,
and the protein product of the G2 allele lose binding afﬁnity with
SRA, suggesting a positive selection and inheritance of both alleles
in populations that once encountered trypanosomal infection
threat [68,70]. These two variants in APOL1 may be beneﬁcial to
individuals living in African regions with T.b. rhodesiense and,
possibly, Trypanosoma brucei gambiense, enabling them to resist
African sleeping sickness. Consistent with this hypothesis, a case
report documented an Indian patient whose serum lacked func-
tional ApoL1 and lost trypanolytic activity. The patient was
infected by a serum-sensitive Trypanosoma evansi, a strain that
would normally not infect humans [101]. Mutation analysis
showed that the patient had two frameshift mutations, K142fs
and L266fs, resulting in loss of detectable ApoL1 protein in the
serum (Fig. 2B). Thus, with apparent autosomal recessive
inheritance, one copy of an APOL1 G1 or G2 risk variant provides
protection from African sleeping sickness, whereas possession of
two APOL1 risk variants, leads to FSGS, HIVAN and hypertensive
nephrosclerosis.
7. ApoL1 in hypertensive nephrosclerosis, FSGS, HIVAN, and
kidney transplantation
As discussed above, a spectrum of three renal diseases, hyper-
tensive nephrosclerosis (arteriolar nephrosclerosis and hyperten-
sion-attributed ESKD), FSGS, and HIVAN have been linked to the
presence of the APOL1 risk alleles. A remarkable observation is that
the link between nephrosclerosis and hypertension in African
American patients (labeled hypertensive nephrosclerosis), could
be now explained, at least in part, by the APOL1 risk variants
[38]. Nephrosclerosis is the result of scarring of the renal
parenchyma, and is associated with pathological changes occurring
in the preglomerular microvasculature and the secondary involve-
ment of glomeruli and interstitium. These patients typically
C.-A.A. Hu et al. / FEBS Letters 586 (2012) 947–955 953present with advanced disease and it is difﬁcult to determine the
original process that initiated the renal disease. Therefore, nephrol-
ogists usually assume that hypertension is responsible for the
development of nephrosclerosis in approximately 25% of the
patients with ESKD. Recent studies have documented the expres-
sion of ApoL1 protein in preglomerular vessels, a key renal struc-
ture involved in the pathogenesis of hypertension-attributed
nephrosclerosis [40]. Moreover, the family clustering of ESKD
attributed to hypertension in African Americans can now be
explained by the APOL1 risk alleles. Therefore, the APOL1 genetic
variation is associated with more than a sevenfold increase in risk
for hypertension-attributed ESKD [102]. These ﬁndings also
suggest that mild to moderate elevations in blood pressure per
se, might not be the primary cause responsible for the develop-
ment of nephrosclerosis.
HIVAN is a renal disease characterized by severe proteinuria
associated with FSGS, frequently presenting the collapsing pheno-
type, and microcystic tubular dilatation leading to renal enlarge-
ment and rapid progression to ESKD [103,104]. At the cellular
level, HIVAN is characterized by the loss, hypertrophy, and prolif-
eration of glomerular and tubular epithelial cells. Histological
studies have shown HIVAN to be the predominant lesion in the
2.3 million HIV-1 infected patients living in Sub-Saharan Africa.
Interestingly, the United States Renal Disease System reported that
HIV-1 infected African Americans have a 50 times higher risk of
developing ESKD than HIV-1-infected whites. HIVAN is considered
the most prominent form of non-diabetic kidney disease. Interest-
ingly, the G1 and G2 haplotypes of APOL1 have also been identiﬁed
as risk variants for HIVAN [39,41,103,104]. Changes in the differen-
tiation and proliferation status of glomerular podocytes, parietal
epithelial cells, and tubular epithelial cells are known to play a
key role in the pathogenesis of HIVAN. As stated above, podocytes
require high levels of autophagic homeostasis for cellular integrity
and survival [90], and autophagy-deﬁcient podocytes exhibited
glomerulopathy in aging mice [87], suggesting that autophagy is
a major protective means to maintain functional podocytes and
therefore kidney. It is conceivable that if ApoL1 plays an important
role in regulating autophagy in kidney cells, both gain-of-function
and loss-of-function mutations of APOL1 may disrupt ApoL1-
dependent cellular homeostasis, leading to apoptosis and necrosis.
Furthermore, patients possessing two APOL1 risk alleles have the
highest risk for developing ESKD when infected with HIV-1
[37,39]. Up to date, however, the exact mechanisms by which
HIV-1 induces glomerular epithelial and tubular injury are not
clearly understood. We speculate that cytokines released by
HIV-1-infected cells may play a critical role in this process as well.
Certain cytokines released by HIV-infected cells can upregulate the
expression of ApoL1 in renal epithelial cells and induce apoptotic
and/or proliferative changes in these cells. Overall, these changes
may impair autophagy and disrupt the balance of intracellular
protein degradation and recycling, increasing the susceptibility of
these cells to detach, de-differentiate, and/or proliferate. Thus,
elucidation of the dynamic signaling pathways and ApoL1 interac-
tome may prove useful in designing speciﬁc therapeutic strategies
for many different kidney diseases, and increasing of ApoL1 auto-
phagic signals may provide a treatment for RCC.
Finally, coding-sequence variants in the APOL1 gene appear to
predict the outcome of kidney transplants. A recent study found
that kidneys from African American deceased donors harboring
two APOL1 risk variants failed more rapidly after renal transplan-
tation than those with zero or one risk variant [43]. These studies,
however, has several weaknesses including the small sample size,
lack of genotyping of APOL1 in the recipients, and few post-
implantation biopsies. Therefore, although these ﬁndings need to
be replicated in a larger number of patients, APOL1 genotypingcould improve the donor selection process and the long term out-
come of kidney allograft survival [42].
8. Summary and future perspectives
ApoL1 and ApoL6 are crucial regulators of cellular homeostasis,
death and survival, and disruption of functions of these proteins
may present signiﬁcant clinical complications from cancer to kid-
ney failure. ApoL1, when overexpressed intracellularly, induces
autophagy and autophagy-associated cell death in all cell types
examined thus far including those originated from kidney normal
and cancerous tissues. In contrast, cells stably transfected with
ApoL6 showed mitochondrial-mediated cell death characterized
by the release of cytochrome c and activation of caspases 9 and
8. ApoL6 overexpression also blocked Beclin 1-dependent autoph-
agy. Hypothetically, an elevated ratio of ApoL6:ApoL1 could pro-
mote apoptosis through the inhibition of autophagic signals.
Considering the role of ApoL1 in cellular homeostasis, gain- or
loss-of-function mutations in ApoL1 could increase the risk of cell
death leading to CKD. Furthermore, ApoL1-mediated lipid metabo-
lism could also play a role in CKD. Moreover, HIV-1 infection and
other stresses may act as a second trigger/hit to promote cell death,
which may not be rescued by ApoL1-dependent autophagy in pa-
tients harboring two APOL1 risk alleles. Importantly, from the hu-
man ApoL1 interactome point of view, the I384M mutation is
present in the LZD and therefore may disrupt interaction of ApoL1
with other critical proteins in kidney cells and in the circulation
that lead to pathological consequences of CKD. Thus, understand-
ing the biology and pathophysiology of ApoL1 is of great impor-
tance in the prevention and therapy of RCC and CKD. For the
well-being of the large number of people of African ancestry who
develop kidney disease all over the world, future investigations
should aim at dissecting the molecular mechanisms of ApoL1-asso-
ciated CKD states and the clinical implications of APOL1 genotype
in the setting of proteinuria, FSGS, HIVAN, hypertension-attributed
nephrosclerosis, and clinically ‘‘healthy’’ kidney donors.Acknowledgements
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